Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer’s Disease
June 21 2021 - 4:10PM
Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company
focused on Alzheimer’s disease, today announced the selection of
Premier Research International as its clinical research
organization (CRO) to help conduct the Phase 3 clinical program of
simufilam for Alzheimer’s disease. Consistent with previous
guidance, Cassava Sciences plans to initiate this Phase 3 program
in the second half of 2021.
“Having completed over 250 clinical studies in
neuroscience, we believe Premier Research International understands
how to conduct clinical studies in patients with Alzheimer’s
disease,” said Remi Barbier, President & CEO of Cassava
Sciences. “With Premier Research as our CRO partner, we now look
forward to advance simufilam into Phase 3 clinical testing.”
“Premier Research is pleased to be Cassava
Sciences’ CRO of choice for this pivotal program,” said Krista
Armstrong, Senior Vice President, Clinical Development Services and
Global Head of Neuroscience, Premier Research. “Premier Research
has deep experience in conducting complex studies in neuroscience.
We look forward to bringing our extensive knowledge and experience
in Alzheimer’s disease to Cassava Sciences’ pivotal Phase 3 program
of simufilam.”
About Premier ResearchPremier
Research, a clinical research and development company, is dedicated
to helping biotech, specialty pharma, and device innovators
transform life-changing ideas and breakthrough science into new
medical treatments. For more information, please visit
https://premier-research.com
About Cassava Sciences,
Inc.Cassava Sciences’ mission is to discover and develop
innovations for chronic, neurodegenerative conditions. Over the
past 10 years, Cassava Sciences has combined state-of-the-art
technology with new insights in neurobiology to develop novel
solutions for Alzheimer’s disease. For more information, please
visit https://www.CassavaSciences.com
For More Information
Contact:
Eric Schoen, Chief Financial Officer
eschoen@CassavaSciences.com
(512) 501-2450
Cautionary Note Regarding
Forward-Looking Statements: This news release contains
forward-looking statements, including statements made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, relating to: Premier Research’s contributions
to or ability to conduct the Company’s Phase 3 clinical program;
and the Company’s current intentions to initiate a Phase 3 clinical
program in Alzheimer’s disease in 2021. These statements may be
identified by words such as “may,” “anticipate,” “believe,”
“could,” “expect,” “would”, “forecast,” “intend,” “plan,”
“possible,” “potential,” and other words and terms of similar
meaning.
Drug development involves a high degree of risk,
and historically only a small number of research and development
programs result in commercialization of a product. Clinical results
from our earlier-stage clinical trials may not be indicative of
full results or results from later-stage or larger scale clinical
trials and do not ensure regulatory approval. You should not place
undue reliance on these statements or any scientific data we
present or publish.
Such statements are based largely on our current
expectations and projections about future events. Such statements
speak only as of the date of this news release and are subject to a
number of risks, uncertainties and assumptions, including, but not
limited to, those risks relating to the ability to conduct or
complete clinical studies on expected timelines, to demonstrate the
specificity, safety, efficacy or potential health benefits of our
product candidates, the severity and duration of health care
precautions given the COVID-19 pandemic, any unanticipated impacts
of the pandemic on our business operations, and including those
described in the section entitled “Risk Factors” in our Annual
Report on Form 10-K for the year ended December 31, 2020 and future
reports to be filed with the SEC. The foregoing sets forth many,
but not all, of the factors that could cause actual results to
differ from expectations in any forward-looking statement. In light
of these risks, uncertainties and assumptions, the forward-looking
statements and events discussed in this news release are inherently
uncertain and may not occur, and actual results could differ
materially and adversely from those anticipated or implied in the
forward-looking statements. Accordingly, you should not rely upon
forward-looking statements as predictions of future events. Except
as required by law, we disclaim any intention or responsibility for
updating or revising any forward-looking statements contained in
this news release.
For further information regarding these and
other risks related to our business, investors should consult our
filings with the SEC, which are available on the SEC's website at
www.sec.gov.
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Apr 2023 to Apr 2024